Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy

Journal of Gastroenterology

Volumn 41, Issue 3, 2006, Pages 250-256

  Nanashima, Atsushi ^a   Sumida, Yorihisa ^a   Abo, Takafumi ^a   Shindou, Hisakazu ^a   Fukuoka, Hidetoshi ^a   Takeshita, Hiroaki ^a   Hidaka, Shigekazu ^a   Tanaka, Kenji ^a   Sawai, Terumitsu ^a   Yasutake, Toru ^a   Nagayasu, Takeshi ^a   Omagari, Katsuhisa ^a   Mine, Mariko ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

CLIP score; Hepatocellular carcinoma; JIS score; TNM stage

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER RESECTION; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; JAPAN; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 39049174414     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-005-1751-4     Document Type: Article

References (22)

1. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751-5.
2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329- 37.
3. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-15.
4. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002;94:1760-9.
5. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patient with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31:133-41.
6. Omagari K, Honda S, Kadokawa Y, Isomoto H, Takeshima F, Hayashida K, et al. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:805-11.
7. Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005;54:419- 25.
8. Nanashima A, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Tsuji T, et al. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. Eur J Surg Oncol 2003;29:735-42.
9. Nanashima A, Omagari K, Tobinaga S, Shibata K, Sumida Y, Mine M, et al. Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis. Eur J Surg Oncol 2005;31:882-90.
10. Nanashima A, Sumida Y, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, et al. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatic resection. Eur J Surg Oncol 2004;30:765-70.
11. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
12. Takasaki T, Kobayashi S, Suzuki S, Muto H, Marada M, Yamana Y, et al. Predetermining postoperative hepatic function for hepatectomies. Int Surg 1980;65:309-13.
13. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resection surgery for hepatic tumors. Hepatology 1997;26:1176-81.
14. Liver Cancer Study Group of Japan: Stage. In: Makuuchi M, editor. The general rules for the clinical and pathological study of primary liver cancer (in Japanese). 4th ed. Tokyo: Kanehara; 2000. p. 19.
15. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974;AC-19:716-23.
16. Helton WS, Strasberg SM. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: rationale and overview of the conference. J Hepatobiliary Pancreat Surg 2003;5:238- 42.
17. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396-405.
18. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41: 707-16.
19. Shiota G, Kishimoto Y, Suyama A, Okubo M, Katayama S, Harada K, et al. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol 1997; 27:661-8.
20. Nakagawa T, Seki T, Shiro T, Wakabayashi M, Imamura M, Itoh T, et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol 1999;14:281-6.
21. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002;17:772-8.
22. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for smallsized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000;32:1224-9.